Skip to Content

Palatin Technologies Inc

Rating as of

Company Profile

Business Description

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.

Contact
4B Cedar Brook Drive
Cranbury, NJ, 08512
T +1 609 495-2200
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2020
Fiscal Year End Jun 30, 2020
Stock Type Speculative Growth
Employees 18